Compare ADMA Biologics Inc (ADMA) vs iShares MSCI South Korea ETF (EWY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs iShares MSCI South Korea ETF — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while iShares MSCI South Korea ETF trades at $179.45. The key difference: iShares MSCI South Korea ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | EWY | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $20.38 | $219.20 |
52-Week Low | $7.60 | $70.65 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
The iShares MSCI South Korea ETF (EWY) trades at $189.85, up 5.33% over 24 hours, amid volatile South Korean equity markets. Technical indicators show a bearish trend with key support at $185 and resistance at $192. Recent news highlights strong AI-driven semiconductor demand boosting South Korean stocks, but weak EV battery demand and market volatility pose headwinds.
EWY's outlook hinges on AI memory demand and Samsung's performance, with potential gains from SK Hynix's U.S. listing. Risks include semiconductor cycle volatility and foreign investor selling. The ETF remains a high-beta play on South Korea's tech sector, requiring careful risk management amid elevated market swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →
